128 related articles for article (PubMed ID: 11329143)
21. p21 expression predicts outcome in p53-null ovarian carcinoma.
Rose SL; Goodheart MJ; DeYoung BR; Smith BJ; Buller RE
Clin Cancer Res; 2003 Mar; 9(3):1028-32. PubMed ID: 12631602
[TBL] [Abstract][Full Text] [Related]
22. p53 tumor suppressor gene mutation in ovarian cancer in Thai patients.
Neungton N; Neungton S; Leelaphatanadit C; Dangrat C; Soiampornkul R
J Med Assoc Thai; 2002 Jun; 85(6):658-67. PubMed ID: 12322838
[TBL] [Abstract][Full Text] [Related]
23. High frequency of frameshift mutation on p53 gene in Taiwanese with non small cell lung cancer.
Chang MY; Chong IW; Chen FM; Wang JY; Cheng TL; Cheng YJ; Sheu CC; Hung SY; Yang MC; Lin SR
Cancer Lett; 2005 May; 222(2):195-204. PubMed ID: 15863268
[TBL] [Abstract][Full Text] [Related]
24. p53 mutations and human papillomavirus infection in oral squamous cell carcinomas: correlation with overall survival.
Kozomara R; Jović N; Magić Z; Branković-Magić M; Minić V
J Craniomaxillofac Surg; 2005 Oct; 33(5):342-8. PubMed ID: 16129609
[TBL] [Abstract][Full Text] [Related]
25. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma.
Leitao MM; Soslow RA; Baergen RN; Olvera N; Arroyo C; Boyd J
Gynecol Oncol; 2004 May; 93(2):301-6. PubMed ID: 15099937
[TBL] [Abstract][Full Text] [Related]
26. Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast.
Schlichtholz B; Presler M; Matuszewski M
Carcinogenesis; 2004 Dec; 25(12):2319-23. PubMed ID: 15308588
[TBL] [Abstract][Full Text] [Related]
27. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma.
Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D
J BUON; 2007; 12(1):99-104. PubMed ID: 17436409
[TBL] [Abstract][Full Text] [Related]
28. Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.
Alvarez AA; Axelrod JR; Whitaker RS; Isner PD; Bentley RC; Dodge RK; Rodriguez GC
Gynecol Oncol; 2001 Aug; 82(2):273-8. PubMed ID: 11531279
[TBL] [Abstract][Full Text] [Related]
29. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.
Buller RE; Runnebaum IB; Karlan BY; Horowitz JA; Shahin M; Buekers T; Petrauskas S; Kreienberg R; Slamon D; Pegram M
Cancer Gene Ther; 2002 Jul; 9(7):553-66. PubMed ID: 12082455
[TBL] [Abstract][Full Text] [Related]
30. Spontaneous apoptosis in ovarian carcinomas: a positive association with p53 gene mutation is dependent on growth fraction.
Kupryjańczyk J; Dansonka-Mieszkowska A; Szymańska T; Karpińska G; Rembiszewska A; Rusin M; Konopiński R; Kraszewska E; Timorek A; Yandell DW; Stelmachów J
Br J Cancer; 2000 Feb; 82(3):579-83. PubMed ID: 10682669
[TBL] [Abstract][Full Text] [Related]
31. Overexpression and mutation of p53 in epithelial ovarian cancer.
Marks JR; Davidoff AM; Kerns BJ; Humphrey PA; Pence JC; Dodge RK; Clarke-Pearson DL; Iglehart JD; Bast RC; Berchuck A
Cancer Res; 1991 Jun; 51(11):2979-84. PubMed ID: 2032235
[TBL] [Abstract][Full Text] [Related]
32. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.
Westra JL; Schaapveld M; Hollema H; de Boer JP; Kraak MM; de Jong D; ter Elst A; Mulder NH; Buys CH; Hofstra RM; Plukker JT
J Clin Oncol; 2005 Aug; 23(24):5635-43. PubMed ID: 16110022
[TBL] [Abstract][Full Text] [Related]
33. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
[TBL] [Abstract][Full Text] [Related]
34. High frequency of G/C transversion on p53 gene alterations in breast cancers from Taiwan.
Chen FM; Hou MF; Wang JY; Chen TC; Chen DC; Huang SY; Chung YS; Lin SR
Cancer Lett; 2004 Apr; 207(1):59-67. PubMed ID: 15050734
[TBL] [Abstract][Full Text] [Related]
35. Loss of p53 gene mutation after irradiation is associated with increased aggressiveness in recurring head and neck cancer.
Gallo O; Chiarelli I; Bianchi S; Calzolari A; Simonetti L; Porfirio B
Clin Cancer Res; 1996 Sep; 2(9):1577-82. PubMed ID: 9816336
[TBL] [Abstract][Full Text] [Related]
36. Improved survival in women with BRCA-associated ovarian carcinoma.
Cass I; Baldwin RL; Varkey T; Moslehi R; Narod SA; Karlan BY
Cancer; 2003 May; 97(9):2187-95. PubMed ID: 12712470
[TBL] [Abstract][Full Text] [Related]
37. [Detection and sequence analysis of the p53 gene mutation in epithelial ovarian cancer].
Guan X; Lang J; Bian M
Zhonghua Fu Chan Ke Za Zhi; 1998 Mar; 33(3):165-7. PubMed ID: 10682487
[TBL] [Abstract][Full Text] [Related]
38. Clinical significance in molecular detection of p53 mutation in serum of patients with colorectal carcinoma.
Ito T; Kaneko K; Makino R; Konishi K; Kurahashi T; Ito H; Katagiri A; Kushima M; Kusano M; Mitamura K; Imawari M
Oncol Rep; 2003; 10(6):1937-42. PubMed ID: 14534722
[TBL] [Abstract][Full Text] [Related]
39. [Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer].
Cai Z; Li YF; Liu FY; Feng YL; Hou JH; Zhao MQ
Ai Zheng; 2007 Mar; 26(3):312-7. PubMed ID: 17355798
[TBL] [Abstract][Full Text] [Related]
40. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
